Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 994 8250

Website: minktherapeutics.com

Address:

149 Fifth Avenue, Suite 500, New York, United States

Outcomes Jan. 24 at 2:58 PM

$MNKD $UTHR $INKT $IRBX Very interesting comments about IPF....7:00 'This could be revolutionary'....... 'It's a great unmet need' Think.... immunocompromise....cancer, pulmonary fibrosis, diabetes, Covid.... 22:00 comments are JUST WOW! https://www.youtube.com/watch?v=FK76dUIRvh0

0 · Reply

Outcomes Jan. 24 at 1:06 PM

$IBRX $INKT ....how cozy is this??

0 · Reply

Spartrap Jan. 24 at 11:54 AM

$INKT I find the setup here really interesting so I'll mention it just once for anyone that follows me and is in search of ideas. 5 mil float with explosive potential (cf. July 25), half-owned by AGEN which is in need of capital and would very probably agree to a sale (~$250M + CVRs?), well capitalized for 26 with many possible readouts on their interesting allogeneic NKT IO cell therapy, and now CEO seemingly getting all warm and fuzzy with $6B MC co IBRX. Does it all have a slightly scammy, Armenian mafia undertone? Definitely. Is it worth a small bet? Think of it what you want

0 · Reply

SuperGreenToday Jan. 24 at 4:03 AM

$INKT

0 · Reply

PhoenixLights Jan. 24 at 1:04 AM

$IBRX there's more to this story ... PSS got CEO Jennifer Buell ( $INKT ) included in the US-SAUDI Biotech Alliance (and 47 oked it) for a reason. Every PSS dot leads somewhere. Sleuths (and sleuth wannabes) do your thing. Jennifer Buell At The USA-SAUDI Biotech Alliance Inaugural Summit 2026 - OncoDaily https://share.google/4rIBA2e7EnOuWCmuz 🤔

4 · Reply

Guptasulo Jan. 22 at 2:14 PM

$INKT $IBRX $AGEN Jennifer Buell (MINK's) was invited because IBRX is positioning itself as an immune platform company, and MINK’s iNKT represents a complementary control layer of the immune system that works in unison with IBRX’s IL-15/NK platform and potentially with many other immune-based treatments (e.g. cancer, ARDS, GvHD). Her presence signals platform-level complementarity rather than a single-asset relationship, with relevance across oncology and broader immune modulation, including biodefence and emergency immune settings, as well as difficult indications like cold solid tumors where some engineered immune cells struggle to penetrate or reprogram the tumor microenvironment.

1 · Reply

PhoenixLights Jan. 22 at 11:43 AM

$IBRX Since we have a lot more new followers on this board, perhaps there are some professional sleuths who can unravel the mystery or connect the dots as to why the Mink Therapeutics Inc $INKT CEO attended ImmunityBio's Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - ImmunityBio, Inc. The all day conference was held on April 15, 2025. Surely, someone knows something 🤔 https://share.google/jHW2nWy3MbHgOdvFA

4 · Reply

Spartrap Jan. 21 at 11:53 PM

$INKT if agenT-797 is basically expanded unmodified donor iNKT cells, how do they go about getting IP on this? The rest of the concept is fine, limited TCR make them relatively universal, limited immunogenicity may allow them to avoid long enough immune rejectio. But how do you patent this?

2 · Reply

pedmac2000 Jan. 21 at 7:40 PM

$IBRX $INKT $IBRX $AGEN Look at the combination that SA is looking at for IBRX and MINK. Jennifer Buell mentioned at the Saudi Summit: &quot;We saw upon administration first of Anktiva, we saw this profound immune activation… then within about 24-48 hours, we added iNKT cells, and we saw that together, we completely cleared coccidioidomycosis.&quot; This is Anktiva (IBRX) + iNKT (MiNK) used together. Mink is Immune modulator or master key for the Immune system which works in multiple areas such as ARDS(National Defence/Emergency Use + Refractory Cancers) and it ties up well with IBRX.

1 · Reply

enkemm Jan. 21 at 7:16 PM

$INKT Just about 80,000 to 90,000 shares short (1.9%). Volume has been low for the last couple weeks. Me thinks this stock is going to make a nice upward move soon.

0 · Reply

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Nov 20, 2025, 11:42 AM EST - 2 months ago

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

Nov 14, 2025, 12:11 PM EST - 2 months ago

MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript

$MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025$

Nov 7, 2025, 9:00 AM EST - 2 months ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Sep 29, 2025, 7:30 AM EDT - 4 months ago

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

Sep 25, 2025, 7:30 AM EDT - 4 months ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

Sep 18, 2025, 7:30 AM EDT - 4 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

Aug 14, 2025, 4:15 PM EDT - 5 months ago

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:30 AM EDT - 5 months ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Jul 31, 2025, 8:30 AM EDT - 6 months ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Jul 15, 2025, 8:21 AM EDT - 6 months ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jul 11, 2025, 12:33 PM EDT - 7 months ago

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

Jun 10, 2025, 1:33 PM EDT - 8 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 2, 2025, 9:29 AM EDT - 8 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025, 1:21 PM EDT - 9 months ago

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 9 months ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Mar 18, 2025, 11:28 AM EDT - 11 months ago

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:30 AM EDT - 11 months ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 4, 2025, 7:30 AM EST - 11 months ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 11 months ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 1 year ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 18, 2024, 9:45 AM EST - 1 year ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Nov 14, 2024, 10:47 AM EST - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript

Nov 11, 2024, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 1 year ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 1 year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 2:51 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

May 22, 2024, 7:30 AM EDT - 1 year ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 11:07 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:30 AM EDT - 1 year ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 1 year ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 8, 2024, 12:00 PM EDT - 1 year ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 2:20 PM EDT - 2 years ago

MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 2 years ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 2 years ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

$MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

Jan 30, 2024, 8:00 AM EST - 2 years ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Dec 20, 2023, 7:30 AM EST - 2 years ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Nov 9, 2023, 7:00 AM EST - 2 years ago

MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 3, 2023, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Oct 30, 2023, 8:00 AM EDT - 2 years ago

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Sep 27, 2023, 9:05 AM EDT - 2 years ago

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Outcomes Jan. 24 at 2:58 PM

0 · Reply

Outcomes Jan. 24 at 1:06 PM

$IBRX $INKT ....how cozy is this??

0 · Reply

Spartrap Jan. 24 at 11:54 AM

0 · Reply

SuperGreenToday Jan. 24 at 4:03 AM

$INKT

0 · Reply

PhoenixLights Jan. 24 at 1:04 AM

4 · Reply

Guptasulo Jan. 22 at 2:14 PM

1 · Reply

PhoenixLights Jan. 22 at 11:43 AM

4 · Reply

Spartrap Jan. 21 at 11:53 PM

2 · Reply

pedmac2000 Jan. 21 at 7:40 PM

1 · Reply

enkemm Jan. 21 at 7:16 PM

$INKT Just about 80,000 to 90,000 shares short (1.9%). Volume has been low for the last couple weeks. Me thinks this stock is going to make a nice upward move soon.

0 · Reply

Biotechguy21 Jan. 21 at 3:05 PM

$AGEN she has failed at here and now $INKT 🤡🤡🤡🤡🤡🤡

0 · Reply

Guptasulo Jan. 21 at 2:10 PM

$INKT $IBRX $AGEN Look at the combination that SA is looking at for IBRX and MINK. Jennifer Buell mentioned at the Saudi Summit: "We saw upon administration first of Anktiva, we saw this profound immune activation… then within about 24-48 hours, we added iNKT cells, and we saw that together, we completely cleared coccidioidomycosis." This is Anktiva (IBRX) + iNKT (MiNK) used together. Mink is Immune modulator or master key for the Immune system which works in multiple areas such as ARDS(National Defence/Emergency Use + Refractory Cancers) and it ties up well with IBRX.

0 · Reply

Biotechguy21 Jan. 15 at 8:12 PM

$AGEN $INKT two of the worst run companies in all of biotech. Look into them and you can make back! 👀👀🤡🤡🤡🔥🔥😂😂😂💰💰💰💰💰

0 · Reply

2_logs_higher Jan. 14 at 7:45 PM

$AGEN & $INKT, no pr department at either location. We find out me from employees than IR.

1 · Reply

Biotechguy21 Jan. 13 at 6:05 PM

$INKT $AGEN $PTIX all three pos stocks and do you know why? 👀👀🤡🤡😂😂

0 · Reply

Guptasulo Jan. 12 at 1:37 PM

$AGEN $INKT $IMMX $SNSE France just did something extraordinary. They granted national, reimbursed AAC access for Agenus’ BOT + BAL across three different cancers: • MSS colorectal • Platinum-resistant ovarian • Soft-tissue sarcoma That kind of multi-tumor blanket access is extremely rare — it means regulators see a tumor-agnostic immune mechanism, not a one-off drug. This connects directly with MiNK (INKT): Both platforms target immune reprogramming in refractory, “cold” tumors — not chemo, not radiation, but true immune modulation. Together, Agenus + MiNK are building a platform immune engine for cancers that have already failed standard therapies. No chemo. No radiation. Just immune system reboot. This is how next-gen oncology platforms are born.

2 · Reply

Guptasulo Jan. 9 at 6:55 PM

$INKT Why iNKT cells work in solid tumors when CAR-T and vaccines often fail Most cancer immunotherapies struggle in solid tumors because the tumor creates an immune-suppressive environment. CAR-T cells and cancer vaccines depend on recognizing specific tumor antigens. Solid tumors hide or change those targets and shut down the immune cells that reach them. iNKT cells work differently. They do not rely on a single tumor antigen. They recognize stress and danger signals in diseased tissue and then act as master regulators of the immune system. Inside a tumor, iNKT cells: Wake up exhausted T-cells Activate natural killer (NK) cells Reprogram suppressive macrophages Break down the tumor’s immune shield Instead of just attacking the tumor, they restart the immune response inside it. That’s why in MiNK’s Phase 1 studies you see: Tumor infiltration Memory T-cell activation Late, durable immune responses

1 · Reply

Biotechguy21 Jan. 9 at 12:47 PM

$AGEN $IMMX $INKT $SNSE two of these are huge pos stocks. And add $PTIX and you have a trifecta of 💩

0 · Reply

Guptasulo Jan. 9 at 7:00 AM

$INKT $AGEN $IMMX $SNSE INKT here; The University of Wisconsin–Madison + MiNK press release John Tracks shared; https://finance.yahoo.com/new s/mink-therapeutics-university-wisconsin-madison-170000383.html This GvHD trial is funded by NIH (NIAID) STTR + UW philanthropic grants. NIH STTR funding is not early discovery — it is platform validation and expansion. The key is iNKT cells — MiNK’s off-the-shelf immune regulators that are already being tested in: • Refractory gastric cancer • Solid tumors • ARDS (severe pulmonary inflammation) • Now GvHD / transplant immune regulation These are all expressions of the same immune engine. 2026 we get: A) RGC 48-week OS update (any time) B) Full 52-week RGC dataset later in the year C) ARDS immune-modulation data D) NIH- and UW-funded GvHD Day-100 readout Combined with $AGEN’s BOT/BAL backbone, this is a multi-indication immune platform being validated by the U.S. government — not a one-drug biotech. This is not a normal microcap biotech.

1 · Reply

Biotechguy21 Jan. 6 at 4:47 PM

$AGEN fake pump. This POS is run by a bunch of 🤡s. Just like $INKT

0 · Reply

Guptasulo Jan. 6 at 2:22 PM

$INKT $IMMX $SNSE INKT; Activity seen where chemo has failed. Responses reported across multiple tumor types (Ph1) Pattern suggests potential platform oncology drug (not single-indication) Platform level; multiple cancer treatments. Ph2 interim expected Jan 2026. Micro-float (~5M OS) and ~$60M market cap.

0 · Reply

Biotechguy21 Jan. 5 at 7:56 PM

$AGEN $INKT want to make a lot of money? Message me 💰💰💰

0 · Reply

Market Cap	58.68M
Revenue (ttm)	0.00
Net Income (ttm)	-9.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	14,000
Avg Vol	16,772
Day's Range	N/A - N/A
Shares Out	4.69M
Stochastic %K	89%
Beta	0.34
Analysts	Strong Sell
Price Target	$39.00